DAFNA Capital Management LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), DAFNA Capital Management LLC reported 81 stock positions worth $389.0 million. Its top holding was SS SPDR S&P Biotech ETF (XBI) at 9.2% of the portfolio, followed by Stereotaxis (STXS, 8.0%) and Revolution Medicines (RVMD, 7.1%). Compared with Q3 2024, it opened 6 new positions, sold out of 8, added to 29 and reduced 20. The biggest buy was Revolution Medicines (RVMD, shares +22%) and the biggest sale Viking Therapeutics (VKTX, shares −49%).
- Most Recent 13F
- Q2 2026
- Location
- LOS ANGELES, CA
- CIK
- 0001389933
- Portfolio Value
- $389.0M (Q4 2024)
- SEC Filing
- 0001389932-25-000004 ↗ filed Feb 14, 2025
Holdings Value
Holdings 81 stocks · $389.0M
| XBI SS SPDR S&P Biotech ETF | 9.20% | 397,505 | $35.8M | Reduce -1.0% |
| STXS Stereotaxis Inc. | 8.02% | 13,680,554 | $31.2M | No change |
| RVMD Revolution Medicines Inc. | 7.10% | 631,176 | $27.6M | Add +21.9% |
| ATRC Atricure Inc. | 5.04% | 641,673 | $19.6M | No change |
| MRUS Merus NV | 4.88% | 451,804 | $19.0M | Add +9.5% |
| CYTK Cytokinetics Inc. | 4.81% | 398,100 | $18.7M | No change |
| ASND Ascendis Pharma A/S | 3.66% | 103,355 | $14.2M | Add +15.4% |
| AXGN Axogen Inc. | 3.59% | 846,882 | $14.0M | Reduce -9.5% |
| IBB iShares Biotechnology ETF | 3.48% | 102,500 | $13.6M | No change |
| BPMC Blueprint Medicines Corp. | 3.36% | 149,763 | $13.1M | Add +23.0% |
| IDYA Ideaya Biosciences Inc. | 3.30% | 498,827 | $12.8M | Add +5.8% |
| XENE Xenon Pharmaceuticals Inc. | 2.76% | 273,739 | $10.7M | No change |
| NBIX Neurocrine Biosciences Inc. | 2.51% | 71,615 | $9.8M | Add +2.9% |
| DAWN Day One Biopharmaceuticals I | 2.38% | 731,363 | $9.3M | Reduce -2.5% |
| BHVN Biohaven Ltd. | 2.11% | 220,235 | $8.2M | Add +17.7% |
| TNDM Tandem Diabetes Care Inc. | 2.07% | 223,208 | $8.0M | Add +9.3% |
| SNDX Syndax Pharmaceuticals Inc. | 1.84% | 542,002 | $7.2M | Add +2.9% |
| KALV Kalvista Pharmaceuticals Inc. | 1.77% | 811,678 | $6.9M | Add +12.2% |
| URGN Urogen Pharma Ltd. | 1.35% | 492,515 | $5.2M | Add +7.3% |
| DXCM Dexcom Inc. | 1.31% | 65,552 | $5.1M | No change |
| BCRX Biocryst Pharmaceuticals Inc. | 1.29% | 667,000 | $5.0M | No change |
| EWTX Edgewise Therapeutics Inc. | 1.28% | 187,140 | $5.0M | Reduce -17.9% |
| TELA Tela Bio Inc. | 1.12% | 1,441,029 | $4.4M | New |
| PRQR Proqr Therapeutics NV | 1.07% | 1,567,561 | $4.2M | Add +73.1% |
| KURA Kura Oncology Inc. | 1.00% | 448,368 | $3.9M | Add +9.8% |
| RCUS Arcus Biosciences Inc. | 0.97% | 254,217 | $3.8M | Reduce -1.0% |
| LKFT Lakefront Biotherapeutic-ADR filed as GALAPAGOS NV | 0.92% | 130,175 | $3.6M | No change |
| ALKS Alkermes PLC | 0.89% | 120,700 | $3.5M | No change |
| PODD Insulet Corp. | 0.83% | 12,400 | $3.2M | Reduce -22.0% |
| ATXS Astria Therapeutics Inc. | 0.69% | 299,775 | $2.7M | Add +17.9% |
| IMVT Immunovant Inc. | 0.69% | 107,996 | $2.7M | Add +107.7% |
| ALLO Allogene Therapeutics Inc. | 0.68% | 1,240,118 | $2.6M | Add +18.1% |
| VKTX Viking Therapeutics Inc. | 0.67% | 64,516 | $2.6M | Reduce -48.6% |
| LXEO Lexeo Therapeutics Inc. | 0.66% | 393,083 | $2.6M | Add +56.9% |
| ARAY Accuray Inc. | 0.62% | 1,222,358 | $2.4M | No change |
| KROS Keros Therapeutics Inc. | 0.53% | 130,316 | $2.1M | Add +76.7% |
| INGN Inogen Inc. | 0.49% | 208,790 | $1.9M | No change |
| STOK Stoke Therapeutics Inc. | 0.49% | 171,097 | $1.9M | Reduce -17.5% |
| BCAX Bicara Therapeutics Inc. | 0.47% | 105,500 | $1.8M | New |
| BWAY Brainsway Ltd.-ADR | 0.47% | 193,208 | $1.8M | Reduce -23.1% |
| MLYS Mineralys Therapeutics Inc. | 0.46% | 146,500 | $1.8M | No change |
| IMTX Immatics NV | 0.45% | 245,000 | $1.7M | Add +69.0% |
| ALEC Alector Inc. | 0.44% | 912,928 | $1.7M | No change |
| IPSC Century Therapeutics Inc. | 0.44% | 1,704,232 | $1.7M | No change |
| BCYC Bicycle Therapeutics PLC-ADR | 0.43% | 120,799 | $1.7M | Reduce -1.1% |
| ITOS Iteos Therapeutics Inc. | 0.37% | 188,347 | $1.4M | Add +16.6% |
| LRMR Larimar Therapeutics Inc. | 0.37% | 371,434 | $1.4M | Reduce -24.9% |
| RGLS Regulus Therapeutics Inc. | 0.36% | 875,200 | $1.4M | Reduce -2.2% |
| AUTL Autolus Therapeutics PLC | 0.35% | 586,667 | $1.4M | Add +20.6% |
| GOSS Gossamer Bio Inc. | 0.33% | 1,409,262 | $1.3M | Reduce -0.7% |
| TSVT 2SEVENTY Bio Inc. | 0.32% | 429,252 | $1.3M | Reduce -31.9% |
| LCTX Lineage Cell Therapeutics Inc. | 0.32% | 2,511,374 | $1.3M | Add +85.9% |
| NGNE Neurogene Inc. | 0.30% | 51,500 | $1.2M | Add +562.4% |
| MDWD Mediwound Ltd. | 0.29% | 64,479 | $1.1M | No change |
| ALGN Align Technology Inc. | 0.29% | 5,500 | $1.1M | New |
| BNTX Biontech SE-ADR | 0.25% | 8,500 | $969K | No change |
| GPCR Structure Therapeutics Inc. | 0.25% | 35,500 | $963K | Add +4.4% |
| SPRY Ars Pharmaceuticals Inc. | 0.24% | 88,790 | $937K | Reduce -40.1% |
| CMPS Compass Pathways PLC | 0.24% | 243,210 | $919K | No change |
| TSHA Taysha Gene Therapies Inc. | 0.23% | 522,500 | $904K | New |
| PYPD Polypid Ltd. | 0.23% | 291,273 | $885K | Reduce -5.6% |
| FHTX Foghorn Therapeutics Inc. | 0.23% | 186,717 | $881K | Add +395.7% |
| PVLA Palvella Therapeutics Inc. | 0.22% | 71,452 | $857K | New |
| STRO Sutro Biopharma Inc. Com SHS | 0.21% | 437,079 | $804K | Add +32.6% |
| CNTA Centessa Pharmaceuticals Ltd. | 0.20% | 47,453 | $795K | Reduce -60.6% |
| VIR Vir Biotechnology Inc. | 0.19% | 100,000 | $734K | New |
| CGEN Compugen Ltd. | 0.18% | 447,202 | $684K | No change |
| ACRV Acrivon Therapeutics Inc. | 0.17% | 112,414 | $677K | No change |
| SAGE Sage Therapeutics Inc. | 0.15% | 108,200 | $588K | No change |
| ACET Adicet Bio Inc. | 0.15% | 600,000 | $577K | No change |
| MASI Masimo Corp. | 0.13% | 3,000 | $496K | No change |
| AQST Aquestive Therapeutics Inc. | 0.12% | 127,000 | $452K | Reduce -78.5% |
| APRE Aprea Therapeutics Inc. | 0.12% | 137,174 | $451K | No change |
| ADCT Adc Therapeutics SA | 0.11% | 224,081 | $446K | Add +9.8% |
| CATX Perspective Therapeutics Inc. | 0.11% | 130,169 | $415K | Reduce -43.5% |
| BDTX Black Diamond Therapeutics I | 0.08% | 140,000 | $300K | Add +12.0% |
| BIOMX INC | 0.08% | 401,136 | $293K | No change |
| SLRN Acelyrin Inc. | 0.07% | 87,989 | $276K | Reduce -85.4% |
| CMPX Compass Therapeutics Inc. | 0.06% | 158,394 | $230K | Add +35.5% |
| NVRO Nevro LLC filed as NEVRO CORP | 0.04% | 38,000 | $141K | No change |
| SPRO Spero Therapeutics Inc. | 0.03% | 125,000 | $129K | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $4.4M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| ASCENDIS PHARMA A/S (ASND 2.25 04/01/28) | NOTE 2.250% 4/0 · principal | 4,000,000 | $4.4M | No change |
Total filed on the 13F, all lines: $393.4M.
Portfolio Sells Q3 2024 → Q4 2024
| VKTX Viking Therapeutics Inc. | Reduce -48.6% | 0.67% | −1.23 |
| SLRN Acelyrin Inc. | Reduce -85.4% | 0.07% | −0.64 |
| CATX Perspective Therapeutics Inc. | Reduce -43.5% | 0.11% | −0.63 |
| AQST Aquestive Therapeutics Inc. | Reduce -78.5% | 0.12% | −0.59 |
| LRMR Larimar Therapeutics Inc. | Reduce -24.9% | 0.37% | −0.40 |
| TSVT 2SEVENTY Bio Inc. | Reduce -31.9% | 0.32% | −0.39 |
| XBI SS SPDR S&P Biotech ETF | Reduce -1.0% | 9.20% | −0.27 |
| SPRY Ars Pharmaceuticals Inc. | Reduce -40.1% | 0.24% | −0.27 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -60.6% | 0.20% | −0.26 |
| NYXH Nyxoah SA | Sold out | 0.00% | −0.25 |
| BCYC Bicycle Therapeutics PLC-ADR | Reduce -1.1% | 0.43% | −0.23 |
| EWTX Edgewise Therapeutics Inc. | Reduce -17.9% | 1.28% | −0.17 |
| GRAL Grail Inc. | Sold out | 0.00% | −0.16 |
| STOK Stoke Therapeutics Inc. | Reduce -17.5% | 0.49% | −0.12 |
| TRML Tourmaline Bio Inc. | Sold out | 0.00% | −0.12 |
| DAWN Day One Biopharmaceuticals I | Reduce -2.5% | 2.38% | −0.11 |
| VSTM Verastem Inc. | Sold out | 0.00% | −0.09 |
| BWAY Brainsway Ltd.-ADR | Reduce -23.1% | 0.47% | −0.09 |
| ADAPY Adaptimmune Therapeutics-ADR | Sold out | 0.00% | −0.08 |
| ANRO Alto Neuroscience Inc. | Sold out | 0.00% | −0.07 |
| STIM Neuronetics Inc. | Sold out | 0.00% | −0.06 |
| PODD Insulet Corp. | Reduce -22.0% | 0.83% | −0.05 |
| KPTI Karyopharm Therapeutics Inc. | Sold out | 0.00% | −0.04 |
| PYPD Polypid Ltd. | Reduce -5.6% | 0.23% | −0.03 |
| GOSS Gossamer Bio Inc. | Reduce -0.7% | 0.33% | −0.01 |
| RGLS Regulus Therapeutics Inc. | Reduce -2.2% | 0.36% | +0.02 |
| RCUS Arcus Biosciences Inc. | Reduce -1.0% | 0.97% | +0.04 |
| AXGN Axogen Inc. | Reduce -9.5% | 3.59% | +0.45 |
Portfolio Buys Q3 2024 → Q4 2024
| RVMD Revolution Medicines Inc. | Add +21.9% | 7.10% | +1.49 |
| TELA Tela Bio Inc. | New | 1.12% | +1.12 |
| PRQR Proqr Therapeutics NV | Add +73.1% | 1.07% | +0.67 |
| BPMC Blueprint Medicines Corp. | Add +23.0% | 3.36% | +0.67 |
| NBIX Neurocrine Biosciences Inc. | Add +2.9% | 2.51% | +0.60 |
| BCAX Bicara Therapeutics Inc. | New | 0.47% | +0.47 |
| ASND Ascendis Pharma A/S | Add +15.4% | 3.66% | +0.46 |
| IMVT Immunovant Inc. | Add +107.7% | 0.69% | +0.33 |
| ALGN Align Technology Inc. | New | 0.29% | +0.29 |
| TSHA Taysha Gene Therapies Inc. | New | 0.23% | +0.23 |
| NGNE Neurogene Inc. | Add +562.4% | 0.30% | +0.22 |
| PVLA Palvella Therapeutics Inc. | New | 0.22% | +0.22 |
| VIR Vir Biotechnology Inc. | New | 0.19% | +0.19 |
| FHTX Foghorn Therapeutics Inc. | Add +395.7% | 0.23% | +0.14 |
| LXEO Lexeo Therapeutics Inc. | Add +56.9% | 0.66% | +0.12 |
| IMTX Immatics NV | Add +69.0% | 0.45% | +0.05 |
| LCTX Lineage Cell Therapeutics Inc. | Add +85.9% | 0.32% | +0.03 |
| ATXS Astria Therapeutics Inc. | Add +17.9% | 0.69% | +0.02 |
| CMPX Compass Therapeutics Inc. | Add +35.5% | 0.06% | +0.01 |
| TNDM Tandem Diabetes Care Inc. | Add +9.3% | 2.07% | −0.00 |
| ITOS Iteos Therapeutics Inc. | Add +16.6% | 0.37% | −0.02 |
| ALLO Allogene Therapeutics Inc. | Add +18.1% | 0.68% | −0.02 |
| ADCT Adc Therapeutics SA | Add +9.8% | 0.11% | −0.04 |
| MRUS Merus NV | Add +9.5% | 4.88% | −0.04 |
| URGN Urogen Pharma Ltd. | Add +7.3% | 1.35% | −0.04 |
| BDTX Black Diamond Therapeutics I | Add +12.0% | 0.08% | −0.05 |
| STRO Sutro Biopharma Inc. Com SHS | Add +32.6% | 0.21% | −0.07 |
| AUTL Autolus Therapeutics PLC | Add +20.6% | 0.35% | −0.07 |
| GPCR Structure Therapeutics Inc. | Add +4.4% | 0.25% | −0.11 |
| BHVN Biohaven Ltd. | Add +17.7% | 2.11% | −0.12 |
| KALV Kalvista Pharmaceuticals Inc. | Add +12.2% | 1.77% | −0.23 |
| IDYA Ideaya Biosciences Inc. | Add +5.8% | 3.30% | −0.27 |
| KROS Keros Therapeutics Inc. | Add +76.7% | 0.53% | −0.49 |
| SNDX Syndax Pharmaceuticals Inc. | Add +2.9% | 1.84% | −0.58 |
| KURA Kura Oncology Inc. | Add +9.8% | 1.00% | −0.90 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 88 | $524.4M | RVMD, XBI, CMPS, STXS, NKTR |
| Q1 2026 | 82 | $433.7M | RVMD, XBI, STXS, DAWN, ATRC |
| Q4 2025 | 76 | $425.1M | RVMD, XBI, STXS, ATRC, CYTK |
| Q3 2025 | 74 | $399.3M | STXS, XBI, RVMD, CYTK, ATRC |
| Q2 2025 | 75 | $357.2M | XBI, STXS, RVMD, BPMC, MRUS |
| Q1 2025 | 82 | $348.0M | XBI, STXS, RVMD, MRUS, ATRC |
| Q4 2024 | 81 | $389.0M | XBI, STXS, RVMD, ATRC, MRUS |
| Q3 2024 | 83 | $418.6M | XBI, STXS, RVMD, CYTK, MRUS |
| Q2 2024 | 82 | $414.1M | XBI, STXS, MRUS, CYTK, RVMD |
| Q1 2024 | 71 | $434.7M | XBI, STXS, CYTK, IDYA, MRUS |